---
title: "Insider Move: Apnimed Director Makes Bold New Investment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294769081.md"
description: "Apnimed Director Paul Sekhri purchased 12,500 shares worth $200,000 on August 3, 2026, signaling confidence in the company. Apnimed's IPO was priced at $16.00 per share for 12 million shares, upsized from 10 million and set at the high end of the range, indicating strong investor demand for its novel oral therapies for sleep-related breathing disorders."
datetime: "2026-08-04T02:08:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294769081.md)
  - [en](https://longbridge.com/en/news/294769081.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294769081.md)
---

# Insider Move: Apnimed Director Makes Bold New Investment

New insider activity at Apnimed, Inc. ( (APMD) ) has taken place on August 3, 2026.

Director Paul Sekhri of Apnimed, Inc. has significantly increased his stake in the company by purchasing 12,500 shares of its stock in a recent transaction. The total value of this investment amounts to $200,000, signaling a notable show of confidence in Apnimed’s future prospects from within its leadership.

Apnimed Inc. saw notable attention as its IPO was priced at $16.00 per share for 12M shares, with the deal upsized from 10M and set at the high end of the $14.00–$16.00 range. The increased deal size and top-range pricing suggest strong investor demand and confidence in Apnimed’s late-stage pipeline of novel oral therapies for sleep-related breathing disorders, driving recent trading interest.

**More about Apnimed, Inc.**

**YTD Price Performance:** 0%

**Average Trading Volume:** 3,444,667

**Current Market Cap:** $0

### Related Stocks

- [APMD.US](https://longbridge.com/en/quote/APMD.US.md)

## Related News & Research

- [Apnimed director Paul J. Sekhri acquires $200,000 in common shares](https://longbridge.com/en/news/294730912.md)
- [Apnimed adopts new IPO-era bylaws with advance notice rules for shareholder proposals](https://longbridge.com/en/news/294731166.md)
- [BUZZ-Sleep apnea pill developer Apnimed poised to jump in debut after upsized IPO](https://longbridge.com/en/news/294533308.md)
- [BUZZ-Sleep apnea pill developer Apnimed rises in debut after upsized $192 mln IPO](https://longbridge.com/en/news/294535091.md)
- [Apnimed Announces Pricing of Upsized Initial Public Offering](https://longbridge.com/en/news/294441797.md)